Adaptin Bio (APTN) Payables (2022 - 2026)

Adaptin Bio (APTN) has 5 years of Payables data on file, last reported at $1.4 million in Q1 2026.

• For the quarter ending Q1 2026, Payables rose 319.29% year-over-year to $1.4 million; the trailing twelve-month figure through Mar 2026 stood at $1.4 million (up 319.29% YoY), and the FY2025 full-year result was $1.5 million, down 20.67% from the prior year.
• Payables declined to $1.4 million in Q1 2026, from $1.5 million in the prior quarter.
• In the past five years, Payables ranged from a high of $1.9 million in Q4 2024 to a low of $12804.0 in Q4 2022.
• A 5-year average of $646431.1 and a median of $258973.5 in 2024 frame the typical range for Payables.
• Across the five-year window, Payables surged 2245.11% in 2024 and retreated 20.67% in 2025, its largest moves.
• Tracing APTN's Payables over 5 years: stood at $12804.0 in 2022, then soared by 534.78% to $81277.0 in 2023, then surged by 2245.11% to $1.9 million in 2024, then fell by 20.67% to $1.5 million in 2025, then fell by 9.31% to $1.4 million in 2026.
• Business Quant data shows APTN's Payables at $1.4 million in Q1 2026, $1.5 million in Q4 2025, and $1.3 million in Q3 2025.